For immediate release: January 19, 2004
VANCOUVER – Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that it will hold a conference call and webcast at 5:30 a.m. PST (8:30 a.m. EST) on January 20, 2004 to announce a corporate partnership for the Company’s lead product Onco TCS.
About the Conference Call
To participate in the conference call, please dial 416-695-5806 or 1-800-273-9672. The call will be available for replay until January 27, 2004 by calling 416-695-5800 or 1-800-408-3053 and entering the pass code 1520395.
The live or archived webcast can be accessed through the company’s website at www.inexpharm.com.
About Inex Pharmaceuticals Corporation
INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer.
The Company’s lead product, Onco TCS, is a targeted chemotherapeutic combining the Company’s proprietary drug delivery technology with the off-patent anticancer drug vincristine. The TCS technology provides prolonged blood circulation, tumor accumulation and extended drug release at the cancer site. These characteristics are designed to increase the effectiveness and reduce the side effects of the encapsulated drug.
INEX investor contact:
Ian Mortimer
Director, Investor Relations
Inex Pharmaceuticals Corporation
Tel: 604.419.3200
Email: info@inexpharm.com
Website: www.inexpharm.com
INEX media contact:
Miriam Zitner
James Hoggan & Associates Inc.
Tel: 604.739.7500
Email: mzitner@hoggan.com
INEX’s common shares are traded on the Toronto Stock Exchange under the trading symbol “IEX”.
